Merck's Keytruda Plus Eisai's Lenvima Could Open New Standard of Care in Renal Cancer

Merck's Keytruda Plus Eisai's Lenvima Could Open New Standard of Care in Renal Cancer

Source: 
BioSpace
snippet: 

Merck presented new data from the Phase III CLEAR trial (KEYNOTE-581/Study 307) at the virtual 2021 Genitourinary Cancers Symposium (ASCO GU) of its checkpoint inhibitor Keytruda (pembrolizumab) and Eisai’s tyrosine kinase inhibitor Lenvima (lenvatinib) in renal cell carcinoma. The data was also published in the New England Journal of Medicine.